MedTrace Logo

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

NCT02828020 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1672

Last updated 2019-01-03

Study results available
· View outcomes & findings →

Summary

This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.

Conditions

  • Migraine, With or Without Aura

Interventions

DRUG

Ubrogepant

50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

DRUG

Placebo-matching Ubrogepant

Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Adele Thorpe · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-22
Primary Completion
2017-12-13
Completion
2017-12-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02828020 on ClinicalTrials.gov